SeekingAlpha · Aug 11, 2026
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call August 11, 2026 9:00 AM EDTCompany ParticipantsBehnam Shamsian - Investor RelationsBrian Carrico - President,...
NR
NASDAQ · NRXS
NeurAxis, Inc.
Healthcare · Biotechnology
$6.94
Up+$0.69 (+9.94%)
Updated Sep 17, 2026, 10:34 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 28.12M
- P/E ratio
- -3.46
- Dividend yield
- 0.00%
- 52-week range
- $2.21 – $9.33
- Volume
- 1.08M
- Avg. volume
- 388.77K
Price performance
NRXS price history
1M range · 20 trading sessions · Daily adjusted prices
NRXS closed at $6.94 after 20 trading sessions, up 8.78% for the selected period.
- Last close
- $6.94
- Period change
- +8.78%
- Period low
- $5.69
- Period high
- $6.94
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $6.14 | $7.74 | $6.14 | $6.94 | 1.08M |
| Sep 15, 2026 | $5.74 | $5.87 | $5.6101 | $5.70 | 77.31K |
| Sep 14, 2026 | $5.69 | $6.00 | $5.31 | $5.75 | 179.9K |
| Sep 11, 2026 | $5.77 | $5.77 | $5.645 | $5.74 | 46.31K |
| Sep 10, 2026 | $5.70 | $5.7252 | $5.57 | $5.69 | 50.25K |
| Sep 9, 2026 | $5.91 | $5.91 | $5.70 | $5.73 | 36.35K |
| Sep 8, 2026 | $6.01 | $6.035 | $5.8146 | $5.91 | 54.55K |
| Sep 4, 2026 | $6.01 | $6.08 | $5.935 | $5.96 | 47.23K |
| Sep 3, 2026 | $6.06 | $6.12 | $5.96 | $6.07 | 69.94K |
| Sep 2, 2026 | $5.81 | $6.09 | $5.81 | $5.95 | 79.69K |
| Sep 1, 2026 | $5.98 | $6.01 | $5.72 | $5.81 | 59.56K |
| Aug 31, 2026 | $6.00 | $6.06 | $5.89 | $6.01 | 52.62K |
| Aug 28, 2026 | $6.06 | $6.105 | $5.94 | $6.00 | 40.21K |
| Aug 27, 2026 | $6.04 | $6.15 | $5.90 | $6.02 | 82.68K |
| Aug 26, 2026 | $6.03 | $6.195 | $5.96 | $5.96 | 64.78K |
| Aug 25, 2026 | $6.10 | $6.23 | $6.00 | $6.04 | 73.9K |
| Aug 24, 2026 | $6.20 | $6.22 | $6.00 | $6.07 | 34.2K |
| Aug 21, 2026 | $6.27 | $6.34 | $6.15 | $6.15 | 96.7K |
| Aug 20, 2026 | $6.36 | $6.36 | $5.99 | $6.27 | 109.07K |
| Aug 19, 2026 | $6.27 | $6.39 | $6.14 | $6.38 | 58.88K |
Latest NRXS news
The latest Smart Investors Daily articles mentioning NRXS.
Stock researchCompany · Overview
NRXS research
Overview
Company profile and research snapshot.
Company profile
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.00
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 20, 2026 | Craig-Hallum | Buy | — |
| Dec 22, 2025 | Craig-Hallum | Buy | — |
| Jun 16, 2025 | Craig-Hallum | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Neuraxis Q2 EPS $(0.19) Beats $(0.32) Estimate, Sales $1.929M Miss $2.000M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.32) by 40.63 percent. This is a 13.64 percent increase over losses of $(0.22) per share from the same
zacks.com · Nov 17, 2025
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth
NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
